 |
|
|
| |
Efficacy and Safety of the HIV-1 Maturation Inhibitor GSK3640254 + 2 NRTIs in Treatment-Naive Adults: 24-Week Results From the Phase IIb, Dose-Range Finding DOMINO Study
|
| |
| |
EACS 2023 Oct 20
Samit R. Joshi,1 Ezequiel Cordova,2 Essack Mitha,3 Antonella Castagna,4 Moti Ramgopal,5 Josep M. Llibre,6 Anja Potthoff,7 Oksana E. Chernova,8 Sebastian A. Nuñez,9 Choy Man,10 Jerry L. Jeffrey,10 Cindy Fishman,11 James Oyee,12 Aditya Joshi,13 Ying Zhang,11 Veronica Bainbridge,12 Brian Wynne,10 Max Lataillade1
1ViiV Healthcare, Branford, CT, USA; 2Fundación IDEAA, Buenos Aires, Argentina; 3Newtown Clinical Research Centre, Johannesburg, South Africa;
4San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy; 5Midway Immunology and Research Center, Fort Pierce, FL, USA;
6Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; 7Interdisciplinary Immunological Outpatient Clinic, Center for Sexual Health and Medicine, Department of Dermatology, Venereology and Allergology, Ruhr Universität Bochum, Bochum, Germany; 8Samara Regional Clinical Center for Treatment and Prophylaxis of AIDS and Infectious Diseases, Samara, Russia; 9Centro Médico Maffei & Investigación Clínica Aplicada, Buenos Aires, Argentina;
10ViiV Healthcare, Durham, NC, USA; 11GSK, Collegeville, PA, USA; 12GSK, Brentford, UK; 13GSK, Bangalore, India
Also attached pdfs
A phase I, first-in-human study investigating the safety,
tolerability, and pharmacokinetics of the maturation inhibitor
GSK3739937
A phase I, first-in-human study investigating the safety,
tolerability, and pharmacokinetics of the maturation inhibitor
GSK3739937
|
| |
|
|
|
|
|
